Aim of this project is the building-up of an integrated model of multidisciplinary research tools to support large-scale and high-quality disease-based studies.
Biologics have revolutionized rheumatoid arthritis (RA) management, with a great impact on patient that justifies treatment with these high-cost drugs. Nevertheless, timing and proper therapeutic decision making remain the main challenge in clinical practice. Pharmacogenetics approach might open promising perspectives, increasing our understanding on genetic-related drug efficacy. Nevertheless, to ensure feasibility and reliability of translational applications of this strategy in clinical practice, large population-based research studies represent a crucial key step. Objectives Major aim of this project is the building-up of an integrated model of multidisciplinary research tools to support large-scale and high-quality disease-based studies. The main targets of this proposal will be: * to develop a disease-based biobank, integrated with already established Emilia-Romagna regional RA Registry, providing a large-scale prospective collection and storing of multiple biological samples * to perform a pharmacogenetic study analyzing a panel of gene variants potentially influencing the response to Tumor Necrosis Factor (TNF) blockers. Methods * Biobank development. A step-wise plan will be considered for: designing biobank governance frame-work, defining Standard Operating Procedures, implementing information system resources. All these procedures will be applied for collecting, processing and storing biological samples of patients included in regional RA registry. * Pharmacogenetic study. A panel of candidate gene variants will be studied in genomic DNA from 300 patients enrolled in the regional RA registry. The association between genotypes and response to biological drugs will be assessed by data-mining approach, and a predictive model will be defined. Expected Results This proposal will create a disease-based biobank, tightly integrated with the already established Emilia-Romagna regional RA Registry, and pave the way towards personalized therapy applications in Rheumatology.
Study Type
OBSERVATIONAL
Enrollment
600
Collection of biological samples (blood, serum, plasma) form patient enrolled in the Emilia Romagna rheumatoid arthritis registry and genotyping genomic DNA samples, and assessing the association between genotypes and response to biological drugs, using multivariate and data-mining approaches that includes also clinical and demographic parameters.
Rheumatology Unit IRCCS Orthopedic Rizzoli Institute
Bologna, BO, Italy
Rheumatology Unit, Internal Medicine Department of Internal Medicine and Nephrology diseases and Aging
Bologna, BO, Italy
Rheumatology Unit, Department of Internal Medicine Buflini Hospital
Cesena, FC, Italy
Biobank creation
Collection of biological samples from patients included into Emilia Romagna Rheumatoid Arthritis Registry
Time frame: through study completion, an average of 5 years
Identification of genes potentially predictive of response to biological drugs
Pharmacogenetics analysis of genes involved in the response to biological drugs
Time frame: at 12 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Medical Genetics Unit, Dept. of Biomedical and Specialty Surgery
Ferrara, FE, Italy
Rheumatology Unit S.Anna University Hospital
Ferrara, FE, Italy
Rheumatology Unit, Internal Medicine Department Morgagni Hospital
Forlì, Fo, Italy
Unit of Internal Medicine, Medical Internistic Department Ospedale Santa maria delle croci
Ravenna, RA, Italy
Division of Rheumatology Azienda Ospedaliera-IRCC S, Reggio Emilia
Reggio Emilia, RE, Italy
Department of Internal Medicine Infermis' Hospital
Rimini, RN, Italy
Laboratory of Immunorheumatology and Tissue Regeneration IRCC Rizzoli Orthopedic Institute
Bologna, Italy